Unaudited Interim Results For The Six Months Ended 31 December 2024
31 March 2025
Bioventix plc (“Bioventix” or the “Company”) Unaudited Interim Results for the six months ended 31 December 2024 To…
Stay up to date with our recent press releases, Shareholder meetings and any investor related announcements.
31 March 2025
Bioventix plc (“Bioventix” or the “Company”) Unaudited Interim Results for the six months ended 31 December 2024 To…
8 November 2024
Bioventix plc (“Bioventix” or the “Company”) Posting of Annual Report and Notice of AGM Bioventix plc (AIM: BVXP),…
28 October 2024
Director’s report and financial statements for the year ended 30th June 2024. To download this report as a PDF…
4 April 2024
Interim Report and Financial Statements for the 6 months to 31 December 2023 To download this report as…
10 November 2023
Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for…
30 October 2023
Director’s report and financial statements for the year ended 30th June 2023. To download this report as a PDF…
3 April 2023
Interim Report and Financial Statements for the 6 months to 31 December 2022 To download this report as…
8 December 2022
Bioventix plc (“Bioventix” or the “Company”) Result of AGM Bioventix plc (AIM: BVXP) announces that at its Annual…
8 November 2022
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications…
24 October 2022
Director’s report and financial statements for the year ended 30th June 2022. To download this report as a PDF…
28 March 2022
Interim Report and Financial Statements for the 6 months to 31 December 2021 To download this report as…
10 December 2021
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly…